Healthcare

Amcor develops and produces consumer packaging and dispensing solutions, including flexible and rigid packaging, cartons and closures, for nutrition, health, beauty and wellness categories. It describes operations across about 400 locations in more than 40 countries, with 75,000 employees and about $23 billion in …

BlueScope is a steel manufacturer with operations in Australia, New Zealand, North America and Southeast Asia. Its brands include COLORBOND and TRUECORE steel in Australia, and it holds a land portfolio of about 1,200 hectares.

Prescient Therapeutics is a Melbourne-based, clinical-stage oncology company developing personalised cancer treatments through targeted therapies and cell therapy enhancement platforms. Its lead asset, PTX-100, is described by the company as a first-in-class compound that blocks an enzyme known as geranylgeranyl transferase-1 (GGTase-1), disrupting oncogenic …

Recce Pharmaceuticals Ltd, listed on the ASX and the Frankfurt Stock Exchange (FSE:R9Q), is developing what it calls a new class of synthetic anti-infectives aimed at antibiotic-resistant superbugs. Its pipeline includes three patented, broad-spectrum synthetic polymer anti-infectives: RECCE 327 (R327), an intravenous and topical …

Alterity Therapeutics is a clinical-stage biotechnology company that is also listed on theNasdaqunder the ticker ATHE. It is based in Melbourne, Australia, and San Francisco, California. The company says it is focused on developing disease-modifying therapies for Parkinson’s disease and related disorders.

Starpharma is a biotechnology company advancing dendrimer technology, with shares quoted on the ASX and its American depositary receipts on the US OTC market under SPHRY. Its DEP drug delivery platform is applied to oncology programs. Petalion was established in 2024 as an asset-centric …

Invion is developing Photosoft for cancers, atherosclerosis and infectious diseases. On 21 April 2026 the company announced that its non-melanoma skin cancer trial, INV043, had been expanded to include basal cell carcinoma patients, reporting encouraging preliminary signals. The June 2026Quarterly Reportdid not give data …